Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 188.15 Million EUR | 25.11% |
| 2022 | 148.75 Million EUR | 53.16% |
| 2021 | 97.12 Million EUR | 21.3% |
| 2020 | 80.07 Million EUR | 460.87% |
| 2019 | 14.27 Million EUR | 196.12% |
| 2018 | 4.82 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 49.87 Million EUR | -6.52% |
| 2024 Q2 | 50.94 Million EUR | 2.14% |
| 2024 Q3 | 51.12 Million EUR | 0.37% |
| 2023 Q4 | 53.35 Million EUR | 21.3% |
| 2023 Q2 | 46.42 Million EUR | 9.59% |
| 2023 Q3 | 43.98 Million EUR | -5.25% |
| 2023 Q1 | 42.35 Million EUR | 22.51% |
| 2023 FY | 186.11 Million EUR | 25.11% |
| 2022 Q4 | 34.57 Million EUR | -13.33% |
| 2022 FY | 148.75 Million EUR | 53.16% |
| 2022 Q3 | 39.89 Million EUR | 2.28% |
| 2022 Q2 | 39 Million EUR | 10.53% |
| 2022 Q1 | 35.28 Million EUR | 34.66% |
| 2021 Q2 | 26.17 Million EUR | 28.67% |
| 2021 FY | 97.12 Million EUR | 21.3% |
| 2021 Q4 | 26.2 Million EUR | 7.11% |
| 2021 Q3 | 24.46 Million EUR | -6.54% |
| 2021 Q1 | 20.34 Million EUR | -62.29% |
| 2020 Q1 | 6.8 Million EUR | 0.0% |
| 2020 Q3 | 9.69 Million EUR | 0.73% |
| 2020 Q2 | 9.62 Million EUR | 41.45% |
| 2020 Q4 | 53.95 Million EUR | 456.6% |
| 2020 FY | 80.07 Million EUR | 460.87% |
| 2019 FY | 14.27 Million EUR | 196.12% |
| 2018 FY | 4.82 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AroCell AB (publ) | 57.68 Million SEK | -226.194% |
| Devyser Diagnostics AB (publ) | 204.6 Million SEK | 8.038% |
| Immunovia AB (publ) | 291.35 Million SEK | 35.42% |
| Prostatype Genomics AB (publ) | 3.22 Million SEK | -5734.264% |
| SenzaGen AB | 49.67 Million SEK | -278.795% |
| Spermosens AB | 10.72 Million SEK | -1654.359% |